Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Docetaxel, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with docetaxel as a treatment option for the treatment of HER2 positive metastatic breast cancer for patients who have not received chemotherapy for their metastatic disease.
This statement is based on a regulatory approval from the Health Service Executive:
HER2 positive metastatic breast cancer (MBC) in combination with DOCEtaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.